DocWire News Editors

DocwireNews

According to data made available at the annual meeting, secukinumab (SEC) 150 mg provides sustained improvement in signs, symptoms, and physical function for patients with active ankylosing spondylitis (AS) through four years of treatment.In this study, SEC, a fully human monoclonal IgG1 antibody that selectively targets interleukin-17A, also had a favorable safety profile, similar to previous reports.Helena Marzo-Ortega, MD, of the University of Leeds in the United Kingdom, and colleagues presented their research based on the longer-term results from the MEASURE 2 study. The researchers randomized 219&nbsp;patients with AS patients to receive subcutaneous SEC 150 mg or 75 mg or placebo at baseline and at weeks one, two, and three, then every four weeks after week four. At week 16, placebo-treated patients were re&#8209;randomized to receive SEC 150/75 mg. Eighty-five percent of the patients completed the study.Assessments at week 208 included Assessment in Ankylosing Spondylitis Response Criteria (ASAS) 20 and 40, Bath Ankylosing Spondylitis Disease Activity Index, 36-Item Short Form Health Survey Physical Component Summary,&nbsp;and ASAS partial remission. The researchers reported that the outcome measures showed sustained improvements with SEC 150 mg across all endpoints through four years. Improvements were maintained regardless of prior exposure to anti&ndash;tumor necrosis factor (TNF) therapy. The researchers observed greater responses in patients who were na&iuml;ve to anti-TNF therapy.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Secukinumab Improves Signs, Symptoms, and Physical Function in Ankylosing Spondylitis

ACR 2018 Conference

According to data made available at the annual meeting, secukinumab (SEC) 150 mg provides sustained improvement in signs, symptoms, and physical function for patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe